Press Releases

Exclusive Markets’ Mr. Lambros Lambrou Honoured with ‘Top 50 Financial Markets CEO Awards 2024’ in Dubai

October 23, 2024

DUBAI, United Arab Emirates, Oct. 23, 2024 (GLOBE NEWSWIRE) — Exclusive Markets proudly announces that Mr. Lambros Lambrou, CEO of the esteemed organization, has been awarded the prestigious ‘Top 50 Financial Markets CEO Awards’ at the Middle East Financial Markets Awards Ceremony Dubai 2024 – 2nd Edition. This award is not only a testament to his exceptional leadership, […]

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024

October 23, 2024

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 Mont-Saint-Guibert, Belgium – October 22, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company […]

Exclusive Markets Receives Top Honors at International Business Magazine Awards 2024

October 22, 2024

Exclusive Markets Receives Top Honors at International Business Magazine Awards 2024 DUBAI, United Arab Emirates, Oct. 22, 2024 (GLOBE NEWSWIRE) — Exclusive Markets, a globally renowned leader in online multi-asset trading, has once again showcased its commitment to excellence by holding several prestigious awards at the highly esteemed International Business Magazine Awards 2024. The company […]

Exclusive Markets Honoured with “Top Trusted Financial Institution in the Financial Markets” Award in 2024

October 22, 2024

Exclusive Markets Honoured with “Top Trusted Financial Institution in the Financial Markets” Award in 2024 DUBAI, United Arab Emirates, Oct. 22, 2024 (GLOBE NEWSWIRE) — Exclusive Markets, a globally celebrated online multi-asset trading platform, has been awarded the prestigious title of Top Trusted Financial Institution in the Financial Markets, by Top 100 Trusted Financial Institutions at the Middle East […]

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

October 22, 2024

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are up to 175,000 cases of recurrent C. diff. each […]